Introduction Oxaliplatin-induced peripheral neuropathy (OIPN) is a common, dose-limiting toxicity in colorectal cancer treatment, significantly impacting quality of life and long-term functional outcomes. Duloxetine, already proven effective for the treatment of established chemotherapy-induced neuropathy, has been explored as a preventive strategy.
Introduction
Oxaliplatin-induced peripheral neuropathy (OIPN) is a common, dose-limiting toxicity in colorectal cancer treatment, significantly impacting quality of life and long-term functional outcomes. Duloxetine, already proven effective for the treatment of established chemotherapy-induced neuropathy, has been explored as a preventive strategy.
Problem Statement
Despite multiple attempts, there is no established therapy to prevent OIPN. Whether early initiation of duloxetine (30 mg or 60 mg) can reduce the incidence or severity of neuropathy during oxaliplatin-based chemotherapy remains unclear, representing a critical unmet clinical need.
Summary
This randomised, double-blind phase II trial demonstrated that duloxetine, at both 30 mg and 60 mg doses, did not significantly reduce the incidence or severity of OIPN compared to placebo. Response rates were similar across all groups (~65–68%), indicating no preventive benefit. Importantly, duloxetine was well-tolerated with manageable toxicity. Overall, the study confirms that duloxetine should not be used for the prevention of OIPN and highlights the continued lack of effective preventive strategies in this setting.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.